a public good project by the
Synthesis
Company
of California

© 2026

Patricia LoRusso | doi.page

0 works0 citations0 h-index

Patricia LoRusso

Yale Cancer Center(US)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, PARP inhibition in cancer therapy, PI3K/AKT/mTOR signaling in cancer

Most-Cited Works

→ Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study(2012)1,275 cited
→ Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile(2012)1,113 cited
→ Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma(2009)1,108 cited
→ Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449(2009)1,011 cited
→ Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer(2015)829 cited
→ Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer(1999)788 cited

→ Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial(2014)

709 cited

→ First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement(2013)692 cited

→ Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer(2004)637 cited

→ Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial(2002)578 cited